INSYS Therapeutics, Inc. operates as a pharmaceutical company, which develops and commercializes supportive care products. It focuses on utilizing commercial pharmaceutical products that include Subsys, a proprietary sublingual fentanyl spray for BTCP in opioid-tolerant adult patients; and Syndros, a proprietary orally administered liquid formulation of dronabinol for the treatment of CINV and anorexia associated with weight loss in patients with AIDS. The company was founded by John N. Kapoor on June 15, 1990 and is headquartered in Chandler, AZ.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
226
Frequently Asked Questions
What is Market Cap of Insys Therapeutics, Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Insys Therapeutics, Inc. market cap is N/A.
What is the 52-week high for Insys Therapeutics, Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Insys Therapeutics, Inc. 52 week high is $11.65 as of September 10, 2025.
What is the 52-week low for Insys Therapeutics, Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Insys Therapeutics, Inc. 52 week low is $0.142 as of September 10, 2025.
What is Insys Therapeutics, Inc. stock price today?
Insys Therapeutics, Inc. stock price today is $0.2911.
What was Insys Therapeutics, Inc. stock price yesterday?
Insys Therapeutics, Inc. stock price yesterday was $0.2951.
What is the PE ratio of Insys Therapeutics, Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Insys Therapeutics, Inc.’s P/E ratio is None.
What is the Price-to-Book ratio of Insys Therapeutics, Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Insys Therapeutics, Inc. P/B ratio is None.
What is Insys Therapeutics, Inc.'s EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Insys Therapeutics, Inc.'s EBITDA is -2.08.
What is the 50-day moving average of Insys Therapeutics, Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Insys Therapeutics, Inc. 50-day moving average is $2.05.
How many employess does Insys Therapeutics, Inc. has?
